What SURPASS-2 Actually Changes in Clinical Practice

At a glance

| Detail | Value | |---|---| | N | 1,879 | | Population | Adults with T2D on metformin, A1C 7.0%, 10.5% | | Intervention | Tirzepatide 5 mg, 10 mg, or 15 mg SC weekly | | Comparator | Semaglutide 1 mg SC weekly | | Duration | 40 weeks | | Primary endpoint | Change from baseline in A1C | | Key result | All tirzepatide doses were non-inferior and superior to semaglutide 1 mg for A1C reduction (estimated treatment difference: -0.15% at 5 mg, -0.39% at 10 mg, -0.45% at 15 mg; p < 0.001 for superiority at all doses) |

Why This Trial Matters More Than Most Head-to-Heads

Most head-to-head diabetes trials compare a new drug against placebo or an older standard. SURPASS-2 did something harder: it put tirzepatide directly against semaglutide 1 mg, which was already the top-performing injectable GLP-1RA on the market. That design choice made the results immediately actionable for clinicians who were already comfortable prescribing semaglutide and needed to know whether switching or starting with tirzepatide was worth it.

The trial was powered for both non-inferiority and superiority on A1C, and it cleared both bars at all three tirzepatide doses. That is a high statistical hurdle. It also reported weight loss as a key secondary endpoint, which matters because payers, patients, and guidelines increasingly treat glycemic control and weight management as linked goals in T2D.

Methodology Details That Shape Interpretation

Dose Selection and the Semaglutide 1 mg Question

The comparator was semaglutide 1 mg, not 2 mg. At the time the trial was designed, 1 mg was the approved and most commonly used dose. Semaglutide 2 mg (approved later via SUSTAIN FORTE) did not exist as a marketed option. Critics have pointed out that comparing tirzepatide 15 mg against semaglutide 1 mg is not a symmetric dose comparison. That criticism is fair, but it does not erase the clinical relevance: the 5 mg tirzepatide dose, the lowest tested, still beat semaglutide 1 mg on A1C. The 5 mg-to-1 mg comparison is the most conservative and still showed superiority.

Titration Schedule

Tirzepatide arms started at 2.5 mg and escalated every 4 weeks. Semaglutide started at 0.25 mg, moved to 0.5 mg at week 4, and reached 1 mg at week 8. Both schedules mirror their respective prescribing information (tirzepatide label, semaglutide label). The titration periods were roughly comparable, though tirzepatide's longer ramp means steady-state exposure was reached later. This matters when interpreting early time-point data.

Estimand Framework

SURPASS-2 used two estimands: a treatment-policy estimand (intention-to-treat, includes all data regardless of treatment discontinuation) and an efficacy estimand (on-treatment data only). The primary analysis used the treatment-policy estimand. The difference between the two was small, which suggests that the drug's real-world effectiveness tracks close to its on-treatment efficacy, a sign of decent tolerability and adherence over 40 weeks.

Results Beyond the Abstract

A1C Reduction

| Arm | Baseline A1C | Change from baseline | Patients reaching <7.0% | Patients reaching <5.7% | |---|---|---|---|---| | Tirzepatide 5 mg | 8.28% | -2.01% | 82% | 27% | | Tirzepatide 10 mg | 8.32% | -2.24% | 86% | 40% | | Tirzepatide 15 mg | 8.25% | -2.30% | 87% | 46% | | Semaglutide 1 mg | 8.24% | -1.86% | 79% | 19% |

The <5.7% threshold is worth attention. That number represents a normal, non-diabetic A1C. Nearly half the patients on tirzepatide 15 mg reached it. The clinical meaning of "normoglycemia" in a treated T2D patient is debated (it does not mean the disease is reversed), but it does suggest a degree of glycemic control that was previously uncommon with any single injectable agent.

The HealthRX.com Practice-Translation Matrix

To make SURPASS-2 data actionable, we mapped results against three clinical decision points that practicing endocrinologists and PCPs face weekly:

| Decision Point | What SURPASS-2 Tells You | What It Does Not Tell You | |---|---|---| | New injectable start in T2D on metformin | Tirzepatide 5 mg already outperforms semaglutide 1 mg on A1C and weight. Starting tirzepatide is a reasonable first injectable if access and cost are equal. | Whether tirzepatide outperforms semaglutide 2 mg or oral semaglutide 14 mg. | | Switching from semaglutide 1 mg | Patients not at goal on semaglutide 1 mg may benefit from tirzepatide 10 or 15 mg, based on the magnitude of additional A1C and weight reduction. | Optimal transition protocol (washout vs. direct switch) and real-world tolerability during the switch. | | Choosing between weight loss and glycemic priorities | Both outcomes track together with tirzepatide, so you do not have to choose. The 15 mg dose produced 11.2 kg mean weight loss vs. 5.7 kg with semaglutide 1 mg. | Long-term cardiovascular or renal outcomes (addressed by SURPASS-CVOT, still maturing). |

Weight Loss

| Arm | Mean weight loss (kg) | Mean weight loss (%) | |---|---|---| | Tirzepatide 5 mg | -7.6 | -7.8% | | Tirzepatide 10 mg | -9.3 | -9.6% | | Tirzepatide 15 mg | -11.2 | -11.6% | | Semaglutide 1 mg | -5.7 | -5.9% |

The weight separation between the 15 mg tirzepatide arm and semaglutide 1 mg was roughly 5.5 kg. That gap is large enough to influence body composition, insulin sensitivity, and patient-reported quality of life. It also positions tirzepatide as a dual-purpose agent in a way that prior GLP-1RAs were not, at least not at this magnitude in a T2D population.

Safety and Tolerability

Gastrointestinal adverse events were the most common side effects in all arms. Nausea occurred in 17.4% (5 mg), 19.8% (10 mg), and 22.1% (15 mg) of tirzepatide patients vs. 17.9% with semaglutide 1 mg. Diarrhea and vomiting followed similar patterns. Discontinuation rates due to adverse events were low across all groups (range: 3%, 7%), with the 15 mg tirzepatide arm at the higher end.

Hypoglycemia was rare. Clinically significant hypoglycemia (blood glucose <54 mg/dL) occurred in <1% of patients in any arm, consistent with the known safety profile of incretin-based therapies when not combined with sulfonylureas or insulin.

What Changed in Guidelines After SURPASS-2

ADA Standards of Care

The 2023 ADA Standards of Care updated its pharmacologic treatment algorithm to include dual GIP/GLP-1 agonists (tirzepatide) alongside GLP-1RAs as preferred options for patients with T2D who need additional glycemic control and have overweight or obesity. SURPASS-2 was cited as a key evidence source. The 2024 revision maintained this positioning.

Formulary and Access Shifts

Before SURPASS-2, most commercial formularies carried semaglutide (Ozempic) at a preferred tier. After the trial's publication and Mounjaro's FDA approval in May 2022, payer negotiations intensified. Some large pharmacy benefit managers began placing tirzepatide at a preferred or co-preferred tier. The practical result: patients now sometimes have better copay coverage for one agent over the other based on their specific plan, not on clinical evidence. Clinicians need to check formulary status before writing the prescription.

Real-World Prescribing Patterns

Prescription data from 2023 and 2024 show a rapid uptake of tirzepatide in T2D. IQVIA data indicate that tirzepatide captured a meaningful share of new GLP-1RA starts within 18 months of launch. SURPASS-2's head-to-head framing gave prescribers a direct comparison to cite when justifying prior authorization requests, which accelerated adoption.

Limitations the Authors Acknowledged

The original publication noted several limitations directly:

1. 40-week duration. Long enough to establish glycemic efficacy but not long enough to assess cardiovascular outcomes, durability of weight loss, or long-term safety signals.

2. Semaglutide 1 mg comparator only. The trial does not answer how tirzepatide compares to semaglutide 2 mg, oral semaglutide 14 mg, or other GLP-1RAs like dulaglutide.

3. Open-label design. Patients and investigators knew which treatment they received. This can introduce bias in subjective outcome reporting (nausea severity, quality of life) but is unlikely to meaningfully bias A1C, a laboratory-measured endpoint.

4. Population homogeneity. The trial enrolled predominantly White (56%) and Asian (28%) participants. Black and Hispanic patients were underrepresented relative to the populations who bear the highest T2D burden in the United States.

5. Metformin background. All patients were on metformin. The results may not generalize to patients on other background therapies (SGLT2 inhibitors, sulfonylureas, insulin).

Who in the Trial Population Matches Your Patient

The mean baseline characteristics were: age ~56, BMI ~34, diabetes duration ~8.6 years, A1C ~8.3%. Patients were on stable metformin at ≥1 to 500 mg/day.

If your patient fits this profile, the SURPASS-2 data apply fairly directly. If your patient diverges meaningfully (longer diabetes duration, already on insulin, BMI <30, eGFR <45), you are extrapolating. The SURPASS program includes trials in those populations (SURPASS-3 for insulin-naive patients on metformin with or without SGLT2i, SURPASS-4 for patients on 1-3 oral agents with increased CV risk, SURPASS-5 for patients on basal insulin), but this specific trial does not cover them.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. PubMed
2. Lingvay I, Hansen T, Macura S, et al. Superior efficacy of semaglutide 2.0 mg versus 1.0 mg in SUSTAIN FORTE. Diabetes Care. 2021;44(9):2163-2170. PubMed
3. American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes, 2023. Diabetes Care. 2023;46(Suppl 1). PubMed
4. Tirzepatide (Mounjaro) prescribing information. Eli Lilly and Company. FDA Label
5. Semaglutide (Ozempic) prescribing information. Novo Nordisk. FDA Label
6. Nicholls SJ, Bhatt DL, Buse JB, et al. Tirzepatide and cardiovascular outcomes in type 2 diabetes: SURPASS-CVOT. N Engl J Med. 2024. PubMed